Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003

​Spyre Therapeutics, Inc. (NASDAQ:SYRE) is one of the Hottest Small Cap Stocks to Buy Now. On November 4, Spyre Therapeutics, Inc. (NASDAQ:SYRE) announced positive interim Phase 1 results for SPY003, which is its novel, half-life extended Anti-IL-23 antibody. The treatment is being tested for curing inflammatory bowel disease and rheumatic diseases.

​During the trial, SPY003 showed a half-life of approximately 85 days, supporting maintenance dosing of three or six months. Management noted that the trial was randomized, double-blind, and placebo-controlled with 59 healthy volunteers at various doses. In addition, the drug also demonstrated a favourable safety profile, with no serious adverse events.

​On the same day, Julian Harrison of BTIG maintained Spyre Therapeutics, Inc. (NASDAQ:SYRE) with a Buy rating and a $70 price target. He noted that the extended half-life supports less frequent dosing, which is a critical advancement for SPY003 as a valuable component in combination therapies.

​Moreover, Harrison also mentioned the company’s unique ability to combine multiple monoclonal antibodies into a single treatment. In terms of finances, the analyst noted the company to be well-positioned with a substantial cash runway to fund operations till the second half of 2028.

​Spyre Therapeutics, Inc. (NASDAQ:SYRE) is a clinical-stage biotechnology company that develops antibody-based therapies for inflammatory bowel disease and other immune-related conditions.

While we acknowledge the potential of SYRE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AVAH and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.